RAC 2.20% $1.78 race oncology ltd

Ann: Positive Early Preclinical Ovarian Cancer Results, page-11

  1. 2,725 Posts.
    lightbulb Created with Sketch. 10553
    It is a bit of a borderline decision here. The work is very encouraging, but as we don’t have a committed ovarian cancer program (this is under evaluations as part of Pillar 3) it could be considered not price sensitive. If we were still on the 5-Path strategy (ovarian was path 5) it would have been price sensitive.

    More importantly I am happy to answer any questions about the work you might have.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.